Education
About Us
Working with TipRanks
Follow Us
Vicore Pharma Holding AB (DE:6Y4)
:6Y4
6Y4 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.52 - €1.42
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€208.89M
Enterprise Value€605.02M
Total Cash (Recent Filing)€1.05B
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Aug 22, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding234,579,120
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Vicore Pharma Holding AB News
6Y4 FAQ
What was Vicore Pharma Holding AB’s price range in the past 12 months?
Vicore Pharma Holding AB lowest stock price was €0.52 and its highest was €1.42 in the past 12 months.
What is Vicore Pharma Holding AB’s market cap?
Vicore Pharma Holding AB’s market cap is €208.89M.
When is Vicore Pharma Holding AB’s upcoming earnings report date?
Vicore Pharma Holding AB’s upcoming earnings report date is Aug 22, 2025 which is in 14 days.
How were Vicore Pharma Holding AB’s earnings last quarter?
Vicore Pharma Holding AB released its earnings results on May 06, 2025. The company reported -€0.043 earnings per share for the quarter, missing the consensus estimate of -€0.039 by -€0.003.
Is Vicore Pharma Holding AB overvalued?
According to Wall Street analysts Vicore Pharma Holding AB’s price is currently Overvalued.
Does Vicore Pharma Holding AB pay dividends?
Vicore Pharma Holding AB does not currently pay dividends.
What is Vicore Pharma Holding AB’s EPS estimate?
Vicore Pharma Holding AB’s EPS estimate is -0.04.
How many shares outstanding does Vicore Pharma Holding AB have?
Vicore Pharma Holding AB has 234,579,120 shares outstanding.
What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?
Vicore Pharma Holding AB reported an EPS of -€0.043 in its last earnings report, missing expectations of -€0.039. Following the earnings report the stock price went down -7.895%.
Which hedge fund is a major shareholder of Vicore Pharma Holding AB?
Currently, no hedge funds are holding shares in DE:6Y4
Company Description
Vicore Pharma Holding AB
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Saniona AB
―
Xspray Pharma AB
―
Ownership Overview
―
Insiders
5.01%
Mutual Funds
― Other Institutional Investors
94.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---